EOLS News and Press, Evolus Inc. From 11/01/23

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will present at the following investment conferences in November. Audio webcasts of these events will be available ...

2023-10-27 15:22:19 ET More on AbbVie, Evolus, etc. AbbVie Inc. (ABBV) Q3 2023 Earnings Call Transcript AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans AbbVie: The Humira Loss May Be Fully Priced In After All AbbVie stock...

Oral abstract will be presented on Friday, November 3, 2023 Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sue Ellen Cox M.D. will present final results from the Phase 2 study evaluatin...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, after the U.S. financial markets c...

2023-10-19 13:45:24 ET More on Evolus Evolus: Gaining Market Share Evolus, Inc. (EOLS) Q2 2023 Earnings Call Transcript For further details see: Evolus discloses Medytox sold common shares worth ~$12.7M

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 8,562 shares of Evolus and an aggregate of 46,481 restricted stock units (RSUs) of the ...

2023-09-24 13:01:04 ET The growing popularity of GLP-1 weight-loss drugs may be already impacting demand for certain procedures like body contouring and dermo fillers, according to Needham’s Q3 aesthetics procedures survey. Needham asked respondents who were familiar with GLP-1 d...

2023-09-19 14:18:55 ET Summary Evolus, Inc. provides medical aesthetic products and competes against Botox with its main product, Jeuveau. The company is gaining market share and continues to add members to its core loyalty program. Evolus is expected to deliver 30% annual rev...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will be participating in two investment conferences in September. Event: H.C. Wainwright 25 th Annual Global In...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 83,555 shares of Evolus common st...